Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide in Active SLE
NCT03161483Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of iberdomide in systemic lupus erythematosus (SLE), sponsored by Celgene Corporation. Primary endpoint: SLE Responder Index-4 at 24 weeks. Started Aug 2017; status: completed.
02
Drugs
iberdomide
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03161483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161483.